LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Increased Mean Corpuscular Hemoglobin Concentration Scrutinized for Accuracy

By LabMedica International staff writers
Posted on 21 Dec 2016
Image: The XN-10 RET automated hematology system (Photo courtesy of Sysmex).
Image: The XN-10 RET automated hematology system (Photo courtesy of Sysmex).
In daily practice in hematology laboratories, spurious increased mean corpuscular hemoglobin concentration (MCHC) induces an analytical alarm and needs prompt corrective action to ensure delivery of the right results to the clinicians.

Elevated MCHC is a rare event in routine laboratory practice, but it must be managed properly. In daily practice, the MCHC limit defined by a specific commercial analyzer is fixed at 365 g/L. Exceeding this value leads to a suspicious ‘flag’ and this ‘flag’ has to be considered in an accreditation context to assess the accuracy of reported parameters.

Hematologists at the Hôpital de la Conception (Marseille, France) measured and analyzed in parallel with blood smears from 128 unknown patients with MCHC greater than 365 g/L, all erythrocyte parameters including reticulocyte parameters, chemistry index and osmolality. Differences between optical parameters (RBC-O, HGB-O) and usual parameters (RBC, HGB) obtained by impedance and photometry were also reported.

The scientists used the Sysmex XN-10 RET automated hematology system (Sysmex Corporation, Kobe Japan) that has two different technologies for achieving a full erythrocyte analysis. Erythrocytes are counted using an impedance method with a hydrodynamic focusing system in a fixed volume at room temperature. When required, XN-10 RET can provide a second erythrocyte count (RBC-O) using fluorescence flow cytometry after stabilization and warming at 41 °C in the incubation chamber. RBC-O is a measured parameter, corresponding to total erythrocyte count, including reticulocyte counts, whereas HGB-O is a calculated parameter derived mainly from the RBC-O count and RBC hemoglobin content (RBC-He).

The team classified four groups from their observations: 22 with red blood cell (RBC) agglutination; 17 with optical interference; 18 with RBC disease and 71 others including unclassified and/or patients with hyposmolar plasma. The use of RBC-O and HGB-O permitted efficient correction of the abnormalities when RBC agglutination and/or optical interference were present in 36 of 39 patients. Reticulocyte parameters permitted to elaborate an RBC score that allowed a highly sensitive detection of RBC disease patients (17/18).

The authors concluded that in case of elevated MCHC, their study proves the capability of XN-10 RET optical parameters to provide solutions in the majority of cases, especially concerning RBC cold agglutination and optical interference. The calculated RBC score offers a highly useful tool for managing a blood smear and specifying patients with RBC disease. This original study allows optimization of the workflow in laboratories eliminating manual tasks, guiding biological interpretation in the case of elevated MCHC. The study was originally published online on August 27, 2016, in the International Journal of Laboratory Hematology.

Related Links:
Hôpital de la Conception
Sysmex
Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more